Patents by Inventor Karen S. Aboody

Karen S. Aboody has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10709745
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: July 14, 2020
    Assignees: CITY OF HOPE, UNIVERSITY OF ALABAMA AT BIRMINGHAM, UNIVERSITY OF CHICAGO
    Inventors: Karen S. Aboody, Alexander J. Annala, David Curiel, Maciej Lesniak
  • Publication number: 20190275093
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 12, 2019
    Inventors: Karen S. ABOODY, Alexander J. ANNALA, David CURIEL, Maciej LESNIAK
  • Patent number: 10238699
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 26, 2019
    Assignees: CITY OF HOPE, UNIVERSITY OF CHICAGO, UNIVERSITY OF ALABAMA AT BIRMINGHAM
    Inventors: Karen S. Aboody, Alexander J. Annala, David Curiel, Maciej Lesniak
  • Publication number: 20160317591
    Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.
    Type: Application
    Filed: September 11, 2015
    Publication date: November 3, 2016
    Inventors: Karen S. ABOODY, Alexander J. ANNALA, David CURIEL, Maciej LESNIAK
  • Patent number: 7655224
    Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: February 2, 2010
    Assignees: Children's Medical Center Corp., The General Hospital Corp., Northeastern Ohio Universities COM
    Inventors: Evan Y. Snyder, Xandra O. Breakefield, Karen S. Aboody, Ulrich Herrlinger, William P. Lynch
  • Patent number: 7393526
    Abstract: The present invention relates to the field of cellular and molecular therapy with modified (genetically or growth factor engineered) and unmodified stem cells (SCs). More particularly, the invention relates to a method of systemic treatment of central nervous system (CNS) and other tumors in both intracranial/intraspinal and extracranial/extraspinal sites, using neural stem cells (NSCs), a prototype for solid organ, non-hematopoietic stem cells.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: July 1, 2008
    Assignee: Children's Medical Center Corporation
    Inventors: Evan Y. Snyder, Karen S. Aboody, Alice B. Brown, Xandra O. Breakefield
  • Publication number: 20080152590
    Abstract: One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor/stem cells will migrate through normal tissue and specifically target the tumor cells.
    Type: Application
    Filed: March 7, 2008
    Publication date: June 26, 2008
    Applicant: Children's Medical Center Corporation
    Inventors: Evan Y. Snyder, Karen S. Aboody, Xandra O. Breakefield, William P. Lynch
  • Patent number: 7186409
    Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: March 6, 2007
    Assignees: The Children's Medical Center Corporation, The General Hospital Corporation, Northeastern Ohio Universities College of Medicine
    Inventors: Evan Y. Snyder, Xandra O. Breakefield, Karen S. Aboody, Ulrich Herrlinger, William P. Lynch
  • Publication number: 20040092013
    Abstract: A method of treating Alzheimer's disease provides for administering NSC to a susceptible individual. Preferably the NSCs are administered intracisternally. Other administration routes are spinal injection, ventricular injection or systemic injection. Preferably, the quantity of NSC administered is in a range of about 400,000 to about 40,000,000. More preferably, the quantity of NSC is about 1,000,000 to about 10,000,000. The NSCs are administered at multiple locations. The NSCs can be administered to the neocortex or other affected areas of both hemispheres. The method of preventing further deterioration in cognitive function in a person diagnosed with Alzheimer's disease provides for administering NSC to the person in sufficient quantity to prevent additional loss of cognitive function.
    Type: Application
    Filed: December 6, 2003
    Publication date: May 13, 2004
    Inventors: Evan Y. Snyder, Jeanne F. Loring, Gary L. Snable, Karen S. Aboody, Marcel M. Daadi
  • Publication number: 20020045261
    Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 28, 2001
    Publication date: April 18, 2002
    Inventors: Evan Y. Snyder, Xandra O. Breakefield, Karen S. Aboody, Ulrich Herrlinger, William P. Lynch